Bright Minds Biosciences to Present Data at the American Epilepsy Society 2024 Annual Meeting- Poster presentations on BMB-101 will focus on 5-HT2C functional selectivity and Phase 1 clinical data -
Bright Minds Biosciences Closes US$35 Million Non-Brokered Private PlacementVANCOUVER, British Columbia, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE: DRUG) (
NASDAQDRUG) (“Bright Minds” or the “Company”) announces that further to its news release of October 18, 2024, the Company has closed a non-brokered private placement of 1,612,902 common shares in the capital of the Company (“Shares”) at a price of USD$21.70 per Share for aggregate gross proceeds of USD$35,000,000 (the “Offering”).
Bright Minds Biosciences and Firefly Neuroscience to Collaborate After the BREAKTHROUGH Study: A Phase 2 Trial of BMB-101 in Absence Epilepsy and Developmental Epileptic Encephalopathy for Full Analysis of EEG DataNEW YORK AND VANCOUVER, British Columbia, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (Bright Minds or the Company) (
NASDAQDRUG), a biotechnology company focused on developing novel therapies for neurological and neuropsychiatric disorders, today announced that it is once again collaborating with Firefly Neuroscience, Inc. (Firefly)
NASDAQ: AIFFNASDAQAIFF)
MarketBeat Week in Review – 10/14 - 10/18Stocks struggled for direction, but the trend before tech earnings is still bullish. Nevertheless, investors should expect volatility ahead of the election.
Bright Minds Biosciences (NASDAQ: DRUG) Soars 1800% Amid Short Squeeze Alongside PRSO, ILLR and NIVFThe biotech world is buzzing as Bright Minds Biosciences (
NASDAQDRUG) exploded yesterday with a +1500% surge, rocketing from $2.47 to $38.35 during regular trading, and hitting $50 in after-hours trading—marking a total rise of 1800% in a single day. With its market cap soaring from $4 million to $172 million, this dramatic short squeeze has caught the attention of investors everywhere. Bright Minds, a cutting-edge biotechnology company, is pioneering treatments for neurological and psychiatric disorders, including epilepsy and depression , with its innovative pipeline of selective serotonergic agonists aimed at transforming patient care. DRUG was featured in our pre-market spotlight on 10/15/2024 at just $2.47 per share see more.
Bright Minds Biosciences proprietary compound, BMB-201, 5-HT2C/2A mixed agonist, demonstrated similar efficacy to morphine in preclinical pain modelsNEW YORK, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (
NASDAQDRUG), a pioneering company focused on developing highly selective 5-HT2 agonists for the treatment of drug-resistant epilepsy, depression, and other CNS disorders, is excited to announce positive data from the preclinical testing of BMB-201 completed with National Institute of Health pain screening (PSPP) program.
Bright Minds Biosciences Stock Surges Almost 1,500%Bright Minds Biosciences (
NASDAQDRUG) soared 1,445% in a single day, trading over 100 million shares without any news.
Bright Minds Biosciences announces participation in upcoming scientific conferences and partnering eventsNEW YORK, Oct. 03, 2024 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (
NASDAQDRUG), a pioneering company focused on developing highly selective 5-HT2 agonists for the treatment of drug-resistant epilepsy, depression, and other CNS disorders, is excited to announce its participation in the upcoming scientific conferences:
Bright Minds Biosciences to Host Investor & Analyst KOL Event on September 25thNEW YORK, Sept. 19, 2024 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (NASDAQ / CSE: DRUG) announces the Key Opinion Leader (KOL) event with leading experts in epilepsy research and treatment. The event will include Dr. Dennis Dlugos, Dr. Joe Sullivan, and Dr. Jo Sourbron, who will provide critical insights into the evolving landscape of drug-resistant seizures and the unmet needs in epilepsy care. These thought leaders will explore the scientific innovations driving the Phase 2 BREAKTHROUGH clinical trial design announced last week and highlight the potential for novel treatments.
Bright Minds Biosciences Inc. (NASDAQ: DRUG) Leading the Way in Tuesday Trading Based on Percentage GainBright Minds Biosciences Inc. (
NASDAQDRUG) is one of today’s top gainers. The company’s shares are currently up 46.58% on the day to $4.72.
New Study Reveals Psychedelic Drugs Can Be Almost as Life-Changing as Near-Death ExperiencesA new study undertaken by experts at John Hopkins University School of Medicine has revealed that taking psychedelics can have the same transformational effects as a near-death experience (NDE). The study examined the NDEs of over 3,000 persons who reported changes in their attitude toward death following a psychedelic encounter or a near-death experience. Psilocybin […]
New Study Reveals Psychedelic Drugs Can Be Almost as Life-Changing as Near-Death ExperiencesFN Media Group Presents Microsmallcap.com Market Commentary New York, NY – October 5, 2022 – A new study undertaken by experts at John Hopkins University School of Medicine has revealed that taking psychedelics can have the same transformational effects as a near-death experience (NDE). The study examined the NDEs of over 3,000 persons who […]
